BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) was a blank-check company formed to pursue a business combination in the healthcare and biotechnology sector. The company filed a Form 15-12G with the SEC on October 16, 2023, formally suspending its reporting obligations under Section 12(g) of the Securities Exchange Act, a step that typically follows the wind-down or liquidation of a SPAC that did not complete a qualifying merger within its allotted timeframe. The filing marks the effective closure of the company's registered public entity status. Investors and researchers tracking SPAC lifecycle outcomes, deregistration filings, and sector-specific deal activity can access the full data profile for BioPlus Acquisition Corp. and thousands of other SPACs by signing up at SpacDesk.